Objective Ion channels are involved in a wide range of central nervous system functions and have been implicated in several neuropsychiatric disorders. Rodent studies suggest that the acid-sensing ion channel, ASIC1, may play a role in fear conditioning, a model for human anxiety disorders. In this study, we examined, for the first time, the human analog of ASIC1, the amiloride-sensitive cation channel 2 (ACCN2) gene, for its association with genetic risk across a range of anxiety spectrum phenotypes.
Introduction
Ion channels are involved in a wide range of central nervous system (CNS) functions and have been implicated in several neuropsychiatric disorders (Gargus, 2006) . One subgroup, the acid-sensing ion channels (ASICs), are proton-gated cation channels that are widely distributed in neurons of mammalian CNS and peripheral nervous systems (Alvarez et al., 2002) . As reviewed in Online Mendelian Inheritance in Man (Hamosh et al., 2002) , they are members of the amiloride-sensitive Na + channel/degenerin family of ion channels. Although putatively involved in nociception and taste transduction in the peripheral nervous system, their widespread expression in the CNS also suggests a role in neurotransmission or neuromodulation (Waldmann, 2001 ).
Wemmie and colleagues have investigated the role of ASICs in learning, memory, and fear conditioning. Via genetic manipulation of the ASIC1 gene in laboratory mice, they established its contribution to synaptic plasticity in the hippocampus and to hippocampusdependent learning (Wemmie et al., 2002) . Furthermore, ASIC1 has enriched expression in the amygdala and affects amygdala-dependent behaviors. ASIC1-null mice display deficits in cue and contextual fear conditioning (Wemmie et al., 2003) , whereas transgenic mice that overexpress ASIC1 show enhanced fear conditioning (Wemmie et al., 2004) . As fear conditioning serves as an experimental model for human anxiety disorders, we sought to investigate the potential role of the human analog of ASIC1, the amiloride-sensitive cation channel 2 (ACCN2) gene, across a range of anxiety spectrum phenotypes. The potential role of ACCN2 in anxiety disorders is further strengthened by its chromosomal location 12q13.13, a region which was reportedly linked to a combined panic disorder/agoraphobia phenotype (Smoller et al., 2001) .
Substance Use Disorders (VATSPSUD) (Kendler and Prescott, 1999) . All participants were Caucasian and born in Virginia. Approval of the local Institutional Review Board was obtained before the study and informed consent was obtained from all participants before data collection.
Diagnostic measures
We obtained lifetime psychiatric diagnoses via face-toface or telephone structured psychiatric interview based on the SCID (Spitzer and Williams, 1985) . We used Diagnostic and statistical manual of mental disorder-III-revised (DSM-III-R) (American Psychiatric Association, 1987) diagnostic criteria to assess lifetime major depression, and modified DSM-III-R criteria for lifetime generalized anxiety disorder and panic disorder (Hettema et al., 2001; Kendler et al., 2001a) . Phobia was diagnosed using an adaptation of DSM-III criteria (American Psychiatric Association, 1980) which required the presence of one or more of 22 fears which the respondent recognized as unreasonable and that, in the judgment of the interviewer, objectively interfered with the respondent's life (Kendler et al., 2001b) . We included agoraphobia and social phobia in the phenotypic modeling used for this study (see below). Neuroticism was assessed using the 12 items from the short form of the Eysenck Personality Questionnaire (Eysenck, 1975) via self-report questionnaire. It was analyzed as an ordinal variable with scores from 0 to12.
Sample selection
As described previously (Hettema et al., 2006a) , we used a two-stage association design in which candidate loci were screened in stage 1, the positive results of which were tested for replication in stage 2. Multistage designs have been shown to reduce genotyping burden while adequately controlling false discovery rates ( Van den Oord and Sullivan, 2003) . The parameters for this design were calculated using the LGA program (Robles and van den Oord, 2004 ) to achieve 80% power to detect markers that explained 1% of the variance of the liability distribution whereas controlling the false discovery rate at 0.1.
LGA indicated that we needed about 350 participants in the stage 1 and 1000 in the stage 2 samples, respectively. If any of the markers genotyped in stage 1 met the estimated threshold P value of 0.1 or less, they were then also tested in the stage 2 sample. Note: a more liberal threshold is used for screening markers in stage 1 to reduce false negatives that may result from the lower power of that smaller-sized sample. If a signal from stage 1 represents a true positive, it should be replicated in the larger stage 2 sample.
We have incorporated two novel strategies into our participant selection procedure. First, several authors have proposed using extreme phenotypic selection schemes to maximize the difference in information contained in a sample of participants assessed on continuous measures such as blood pressure or depression scores (Van den Oord, 1999; Schork et al., 2000; Van Gestel et al., 2000) . Unlike these selection schemes based only upon phenotypic extremes, the use of a genetically informative sample containing twins, however, allows for the identification of participants who are at the high and low extremes of genetic risk as well. Selecting participants from the extremes of their underlying genetic risk factor should provide a powerful method for detecting genes of small effect expected to contribute to complex genetic phenotypes like anxiety and related disorders. In addition, we have taken advantage of the extant literature that suggests shared genetic susceptibility among the anxiety disorders, major depression, and neuroticism (Jardine et al., 1984; Scherrer et al., 2000; Middeldorp et al., 2005; Hettema et al., 2006b) . Thus, using multivariate structural equation modeling, we identified twin pairs scoring at the extremes of a latent genetic risk factor for neuroticism that is highly correlated (range 0.6-0.8) with genetic susceptibility to major depression, generalized anxiety disorder, panic disorder, agoraphobia, and social phobia [see Hettema et al. (2006b) for details]. Like phenotypic factor analysis, the factor derived from this analysis combines information across the correlated measures, but in this case uses shared genetic risk as the basis for this combination. For example, some pairs score in the upper tail owing to high genetic loading on major depressive disorder, generalized anxiety disorder, etc. and may have relatively low levels of neuroticism, so this is more than just a selection on neuroticism. One member from each twin pair for whom DNA was available was selected as a case or control based upon scoring above the 80th or below the 20th percentile, respectively, of the genetic factor extracted from the analysis. This produced a total sample size, N = 1128, consisting of 589 cases and 539 controls, of which 376 and 752 were used in stages 1 and 2, respectively. The cases had a mean raw neuroticism score of 6.3 (z score = 1.04) and had the following frequencies of the target psychiatric illnesses: major depressive disorder (80.1%), generalized anxiety disorder (53.8%), panic disorder (20.5%), agoraphobia (14.1%), and social phobia (17.5%). The controls were free of these five disorders and had a mean raw neuroticism score of 0.55 (z score = -0.89). The phenotypic distributions did not differ significantly between the stage 1 and stage 2 samples. Although stage 1 participants were selected so that the sexes were equally distributed to maximize power to detect any sex-specific associations, the stage 2 male-female make-up, however, was about 2 : 1.
Genotyping
Participants were instructed to use standard cytology brushes to obtain buccal epithelial cells for DNA extraction. The method for DNA extraction from the cytology brushes was described previously (Straub et al., 1999) . Single nucleotide polymorphisms (SNPs) were genotyped by the 5 0 nuclease cleavage assay (also called TaqMan method) (Livak, 1999) . Reactions were performed in 384-well plates with 5 ml reaction volume containing 0.25 ml of 20Â Assays-on-Demand SNP assay mix (Applied Biosystems, Foster City, Califonia, USA), 2.5 ml of TaqMan universal PCR master mix, and 5 ng of genomic DNA. The conditions for PCR were initial denaturizing at 951C for 10 min, followed by 40 cycles of 921C for 15 s and 551C for 1 min. After the reaction, fluorescence intensities for reporter 1 (VIC, excitation = 520 ± 10 nm, emission = 550 ± 10 nm) and reporter 2 (FAM, excitation = 490 ± 10 nm, emission = 510 ± 10 nm) were read by the Analyst fluorescence plate reader (LJL Biosystems, Sunnyvale, California, USA). Genotypes were scored by an Euclidian clustering algorithm developed in our laboratory. All genotyped SNPs were checked for deviations from Hardy-Weinberg equilibrium.
The ACCN2 gene spans an interval of 25.9 kB on the long arm of chromosome 12. SNP markers in an approximately 60 kB interval around the ACCN2 gene were selected with the aim to tag the major haplotypes (frequency > 1-2%) observed in the Caucasian (CEU) panel used by the HapMap project (2003) . We used the Tagger module of HAPLOVIEW 3.2 (http://www.broad.mit.edu/personal/ jcbarret/haploview/) (Barrett et al., 2005) with HapMap Phase II data, specifying aggressive tagging of 2-marker and 3-marker haplotypes and a threshold of r 2 = 0.8. We excluded one (rs844359) of the five markers selected by this method owing to its low minor allele frequency (about 1% in our sample, consistent with HapMap data) and supplemented this set with three other markers. In all, we genotyped seven noncoding SNPs in stage 1 and three of these seven in stage 2 (see Results).
Statistical analysis
Pearson's w 2 test was used to test for allelic or genotypic differences by marker between cases and controls in the two stages. We then used the HAPLOVIEW program (Barrett et al., 2005) to find the regions of high linkage disequilibrium (LD) (i.e. haplotype blocks) using the default confidence interval algorithm (Gabriel et al., 2002) . Haplotype association analyses were performed for markers within the same haplotype block with the Cocaphase module of the UNPHASED program (http://www.mrc-bsu.cam.ac.uk/personal/frank/software/unphased/) (Dudbridge, 2003) , as well as on longer range haplotypes (see Results). UNPHASED uses the expectationmaximization algorithm (Excoffier and Slatkin, 1995) to estimate the haplotypes and their frequencies.
Results
The genotype and allele frequencies and results of w 2 association tests for the seven ACCN2 markers genotyped in stage 1 are listed in Table 1 . Markers 1, 2, 5, and 6 were from the original set of five selected using the Tagger module of Haploview, and these were supplemented by markers 3, 4, and 7. None of the SNPs showed deviations from Hardy-Weinberg equilibrium. Figure 1 depicts the relative positions of these markers with respect to the structure of the ACCN2 gene. This 60-kB interval also includes the SMARCD1 and GPD1 loci.
LD information for these markers in our stage 1 sample is provided in Table 2 . To better understand the LD structure, we constructed haplotype blocks using the default block search procedure (Gabriel et al., 2002) in HAPLOVIEW 3.2. We established that markers 2-7 occur on a single haplotype block whereas marker 1 is outside of that block. As indicated in Table 2 , however, significant LD extends across the entire ACCN2 region suggesting the presence of longer haplotypes. We therefore analyzed association of haplotypes created from combinations of all of our SNP markers.
Markers 1 and 3 met threshold criteria of allelic P value less than 0.1 in our stage 1 sample, making this locus a candidate for genotyping in stage 2. In addition, marker 6, when not associated by itself, significantly contributed to haplotype analyses and was therefore retained, together with markers 1 and 3, for genotyping in stage 2. In Table 3 , we present the results, by stage, for the 2-marker and 3-marker haplotypes formed from these SNPs as calculated using the Cocaphase module of UNPHASED. As indicated, several of the marker combinations produced significant haplotypic differences between cases and controls in stage 1, with the most significant differences from the 3-6 combination. None of these associations, however, replicated in stage 2. Similarly, neither marker 1 nor marker 3 showed significant case-control differences in the stage 2 sample (allelic P = 0.384 and 0.569, respectively).
In post hoc exploratory analyses, we tested for associations of marker 3 (rs1108923) and haplotype 2-1 formed from markers 3 and 6 (see Table 3 ) that had the highest significance in stage 1 with specific phenotypes within our total sample (see Table 4 ). Using Cochran-MantelHaenszel tests in the FREQ procedure and regression analysis in the GENMOD procedure in SAS (1999) we were unable to detect associations with generalized anxiety disorder, panic disorder, agoraphobia, social phobia, or neuroticism. We detected a marginally significant effect (P = 0.045, uncorrected for multiple testing) on major depression (N cases = 463) of haplotype 2-1 formed from markers 3 and 6 (see Table 3 ). As we also had specific phobia diagnoses on these participants (N cases = 274), which some researchers may consider the psychiatric phenotype most closely related to fear conditioning, we also tested for association to that, with the same (negative) results. Similarly, post hoc analyses by sex did not reveal any further evidence of association.
Discussion
In this study, we sought to test whether the ACCN2 gene, shown to play a role in an animal model of fear conditioning, is associated with susceptibility to human anxiety spectrum phenotypes, including neuroticism, a range of anxiety disorders, and major depression. This susceptibility was indexed by a latent genetic factor common to these phenotypes, the score of which we derived from multivariate twin modeling and subsequently used to select participants at the extremes of genetic risk. We entered the resulting sample of 589 cases and 539 controls into a two-stage association study in which markers from the candidate locus were screened in stage 1, the positive results of which were tested for replication in stage 2.
Out of a total of seven markers tested in the ACCN2 gene, two met the threshold criterion in stage 1 of P < 0.1, suggesting that this gene was a reasonable candidate for genotyping in stage 2. These two, and a third that was (1) (2) (3) (4) (5)(6)
Seven single nucleotide polymorphism markers genotyped across the ACCN2 locus, with exons and untranslated regions (UTRs) as indicated. Numbers in parentheses correspond to marker numbering referenced in the text.
selected based upon stage 1 haplotype analyses, were then genotyped in the stage 2 sample. None of the markers or haplotypes showing association in stage 1 was, however, significant in the larger stage 2 sample, suggesting that these were likely false positives. As we could not identify any markers or haplotypes that were significant in both stages, we did not perform formal analyses combining the data across the two stages. In an exploratory analysis using our most significant stage 1 haplotype (haplotype 2-1 using markers 3 and 6 from Table 3 ), we estimated a P value of 0.014 in the combined sample (less significant than for the smaller stage 1 sample alone). We also estimated the falsediscovery rate q for this haplotype, that is, the global probability that this level of significance occurred purely by chance, as a function of the assumed earlier probability of true discovery, P 0 (Storey and Tibshirani, 2003) . For reasonable values of P 0 (0.99 or higher, given the large number of possible candidate genes from which to choose), the q value exceeded 0.95, that is, the likelihood of this being a false discovery exceeds 95%. Thus, there is little evidence for association of the ACCN2 gene with these anxiety spectrum phenotypes from our data. Although Smoller et al. (2001) reported significant linkage to a combined panic disorder/agoraphobia phenotype in the region of chromosome 12 in which the ACCN2 gene resides, there are no other human studies with which to compare that examine the relationship between this particular gene and any relevant psychiatric phenotypes.
The results of this study should be interpreted in the context of several potential limitations. First, we investigated the potential association between the ACCN2 gene, the human analog of ASIC1, and participants selected for scoring at the extremes of a latent genetic risk factor shared among a group of anxiety spectrum phenotypes. The original mouse studies, however, implicated ASIC1 in relation to fear conditioning (Wemmie et al., 2003 (Wemmie et al., , 2004 . In fact, the mice strains in which ASIC1 was altered did not show any changes in baseline fear behaviors on the elevated plus maze compared with wild-type mice. Although many researchers consider fear conditioning as a valid experimental model for human anxiety disorders, this dissociation in baseline fear behaviors and fear conditioning suggests that they may not possess significant genetic correlation, at least for this gene. It is also possible that our initial ACCN2 and anxiety Hettema et al. 77 analyses, using our broad phenotypic characterization of shared genetic risk, may not have possessed sufficient sensitivity to detect association owing to heterogeneity between the disorders included. In an attempt to address this, we then explored, via post hoc analyses, possible association of this gene with a broad range of potentially relevant phenotypes, although we did not have direct measures of fear conditioning to include in these. Given the relatively smaller numbers of cases for some of the diagnostic phenotypes, these analyses may not have been sufficiently powered to detect potentially small effects of this gene. Second, although we chose SNP markers to capture the major allelic variation in the ACCN2 locus and tagged all of the common haplotypes, we do not know the effects of this variation on gene expression or ion channel function, the former of which is what was directly altered in the mouse models. Similarly, this analysis would unlikely detect the effects of rare alleles in this gene. Further, there are no nonsynonymous coding SNPs identified in ACCN2, further limiting our ability to sample functional genetic variation. Third, our sample was limited to participants of Caucasian ethnicity, leaving open the possibility that this gene may have significant effects in other ethnic populations. Finally, although a very small effect size for this gene cannot be ruled out, our power analyses suggest that this sample is sufficient to detect genetic effects that account for about 2% of the phenotypic variance. In addition, our genetically based extreme selection strategy should, in principle, enhance the power of this sample compared with standard casecontrol designs that use unselected participants not characterized with respect to comorbidity or genetic risk. An earlier analysis found significant association of the glutamic acid decarboxylase 1 (GAD1) gene with several of our phenotypes using this sample (Hettema et al., 2006a) . Thus, given our inability to detect a significant association signal, it is unlikely that the ACCN2 gene plays a major role in genetic susceptibility shared among the anxiety spectrum disorders investigated in this study.
